Boston Scientific Corp. has agreed to pay an additional $45 million to defuse the legal threat of thousands of patients who say Guidant Corp. knowingly sold defective defibrillator devices.
Boston Scientific, which bought Guidant in 2006, settled more than 4,000 consolidated claims in July for $195 million. After further mediation with U.S. Magistrate Judge Arthur Boylan in Minneapolis, the company signed an amended agreement covering a total of 8,550 patient claims, which the company believes constitute substantially all currently asserted claims in the United States stemming from defects the company revealed in product communications in 2005 and 2006.
Charles Zimmerman, one of the plaintiffs lead attorneys, said in a written statement that the new sum is great news for the patient plaintiffs and will provide them and their families with substantial relief. -- by Gregg Blesch
What do you think? Post a comment on this article and share your opinion with other readers. Submit your letter to Modern Healthcare Online at [email protected]. Please be sure to include your hometown and state, along with your organization and title.